Dow Jones

39 118,86

-0,12%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Abraxis Bioscience (MM) (ABBI)
Abraxis Bioscience (MM) (ABBI) Actualités

ABBI

Abraxis Bioscience (MM) (ABBI)

Abraxis Bioscience (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ABBI

1 2 3 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
12/11/2008	15h00	PR Newswire (US)	Deloitte Names Abraxis BioScience Inc. Fastest Growing Technology Company in Los Angeles Area	NASDAQ:ABBI	Abraxis Bioscience (MM)
12/11/2008	14h00	PR Newswire (US)	Deloitte Unveils 2008 Technology Fast 500 Ranking	NASDAQ:ABBI	Abraxis Bioscience (MM)
13/11/2007	23h02	Edgar (US Regulatory)	Abraxis Bioscience, Inc. (Other) (S-8 POS)	NASDAQ:ABBI	Abraxis Bioscience (MM)
13/11/2007	22h55	Edgar (US Regulatory)	Abraxis Bioscience, Inc. (Other) (POSASR)	NASDAQ:ABBI	Abraxis Bioscience (MM)
13/11/2007	17h19	Edgar (US Regulatory)	Abraxis Bioscience, Inc. (Other) (8-K)	NASDAQ:ABBI	Abraxis Bioscience (MM)
08/11/2007	17h03	Edgar (US Regulatory)	Abraxis Bioscience, Inc. - Current report filing (8-K)	NASDAQ:ABBI	Abraxis Bioscience (MM)
05/11/2007	22h58	Edgar (US Regulatory)	Abraxis Bioscience, Inc. - Prospectus filed pursuant to Rule 424(b)(7) (424B7)	NASDAQ:ABBI	Abraxis Bioscience (MM)
30/10/2007	21h23	Edgar (US Regulatory)	Abraxis Bioscience, Inc. - Statement of Changes in Beneficial Ownership (4)	NASDAQ:ABBI	Abraxis Bioscience (MM)
30/10/2007	21h22	Edgar (US Regulatory)	Abraxis Bioscience, Inc. - Amended Statement of Changes in Beneficial Ownership (4/A)	NASDAQ:ABBI	Abraxis Bioscience (MM)
10/08/2007	14h05	Business Wire	APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection	NASDAQ:ABBI	Abraxis Bioscience (MM)
10/08/2007	02h50	Business Wire	Abraxis BioScience Files Information Statement in Connection with Its Announced Separation into Two Publicly Traded Companies	NASDAQ:ABBI	Abraxis Bioscience (MM)
09/08/2007	14h05	Business Wire	Abraxis BioScience Reports Second Quarter 2007 Revenue of $243 Million versus $161 Million in Prior Year Period	NASDAQ:ABBI	Abraxis Bioscience (MM)
09/08/2007	04h35	Business Wire	Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India	NASDAQ:ABBI	Abraxis Bioscience (MM)
09/08/2007	00h20	Business Wire	Abraxis BioScience Launches Doxorubicin Hydrochloride Injection, USP	NASDAQ:ABBI	Abraxis Bioscience (MM)
07/08/2007	14h00	Business Wire	Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial	NASDAQ:ABBI	Abraxis Bioscience (MM)
06/08/2007	22h15	Business Wire	Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP	NASDAQ:ABBI	Abraxis Bioscience (MM)
06/08/2007	14h00	Business Wire	Abraxis BioScience Acquires from the Buck Institute Exclusive Worldwide Intellectual Property Rights for Technologies Designed t	NASDAQ:ABBI	Abraxis Bioscience (MM)
03/08/2007	00h55	Business Wire	Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL	NASDAQ:ABBI	Abraxis Bioscience (MM)
31/07/2007	22h45	Business Wire	Abraxis BioScience Acquires Manufacturing Facility from Watson	NASDAQ:ABBI	Abraxis Bioscience (MM)
26/07/2007	14h00	Business Wire	Abraxis BioScience and the California NanoSystems Institute Announce Partnership for Collaborative Research in the Development o	NASDAQ:ABBI	Abraxis Bioscience (MM)
19/07/2007	22h05	Business Wire	Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union	NASDAQ:ABBI	Abraxis Bioscience (MM)
16/07/2007	22h05	Business Wire	Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call	NASDAQ:ABBI	Abraxis Bioscience (MM)
02/07/2007	13h05	Business Wire	Abraxis BioScience Announces Plan to Separate Into Two Independent Public Companies	NASDAQ:ABBI	Abraxis Bioscience (MM)
19/06/2007	14h00	Business Wire	Abraxis BioScience Exclusively Licenses Intellectual Property Portfolio Designed to Personalize Treatment for Colorectal Cancer	NASDAQ:ABBI	Abraxis Bioscience (MM)
07/06/2007	14h00	Business Wire	Abraxis BioScience to Present at the Goldman Sachs 28th Annual Global Healthcare Conference	NASDAQ:ABBI	Abraxis Bioscience (MM)
05/06/2007	03h33	PR Newswire (US)	New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treat	NASDAQ:ABBI	Abraxis Bioscience (MM)
02/06/2007	15h05	Business Wire	ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer	NASDAQ:ABBI	Abraxis Bioscience (MM)
30/05/2007	14h05	Business Wire	New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Pr	NASDAQ:ABBI	Abraxis Bioscience (MM)
23/05/2007	14h00	Business Wire	Abraxis BioScience to Present at the Bank of America 2007 Health Care Conference	NASDAQ:ABBI	Abraxis Bioscience (MM)
14/05/2007	22h05	Business Wire	Abraxis BioScience Founder Awarded Ellis Island Medal of Honor	NASDAQ:ABBI	Abraxis Bioscience (MM)